help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on October 11, 2007
Endocrinology, doi:10.1210/en.2007-0583
A more recent version of this article appeared on January 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
149/1/154    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Danaher, R. N.
Right arrow Articles by Cooper, G. J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Danaher, R. N.
Right arrow Articles by Cooper, G. J. S.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH

Submitted on May 2, 2007
Accepted on September 25, 2007

Evidence that alpha calcitonin gene-related peptide is a neurohormone that controls systemic lipid availability and utilization

Rachel N. Danaher, Kerry M. Loomes, Bridget L. Leonard, Lynda Whiting, Debbie L. Hay, Lance Yi Xu, Edward W. Kraegen, Anthony R. J. Phillips, and Garth J. S. Cooper*

School of Biological Sciences and Maurice Wilkins Centre of Research Excellence for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand; Diabetes and Obesity Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; MRC Immunochemistry Unit, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, United Kingdom

* To whom correspondence should be addressed. E-mail: g.cooper{at}auckland.ac.nz.

Alpha calcitonin gene-related peptide ({alpha}CGRP) is released mainly from sensory and motor nerves in response to physiological stimuli. Despite well-documented pharmacological effects its primary physiological role has thus far remained obscure. Increased lipid content, particularly in skeletal muscle and liver, is strongly implicated in the pathogenesis of insulin resistance, but the physiological regulation of organ lipid is imperfectly understood. Here, we report our systematic investigations of the effects of {alpha}CGRP on in vitro and in vivo indices of lipid metabolism. In rodents, levels of {alpha}CGRP similar to those in the blood markedly stimulated fatty acid {beta}-oxidation and evoked concomitant mobilization of muscle lipid via receptor-mediated activation of muscle lipolysis. {alpha}CGRP exerted potent in vivo effects on lipid metabolism in muscle, liver and the blood, via receptor-mediated pathways. Studies with receptor antagonists were consistent with tonic regulation of lipid metabolism by an endogenous CGRP agonist. These data reveal that {alpha}CGRP is a newly recognized regulator of lipid availability and utilization in key tissues and that it may elevate the availability of intramyocellular FFA to meet muscle energy requirements generated by contraction by evoking their release from endogenous TG.


Key words: {alpha}CGRP • lipid metabolism • insulin resistance







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society